Oryzon Genomics SA's total assets for Q4 2024 were €108.72M, a decrease of -11.37% from the previous quarter. ES:ORY total liabilities were €21.67M for the fiscal quarter, a -16.01% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.